SeQure DX
Company

SeQure DX

Biotechnology Research 1440 Main St 17 employees
Employees
17
Contacts
3
Emails
3

SeQure DX Overview

Headquarters
1440 Main St
Website
maxcyte.com
Industry
Biotechnology Research
Employees
17
Founded
2021
Funding
17.5M
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About SeQure DX

SeQure DX™ is setting the standard for precision analytics in gene editing, delivering best-in-class off-target risk assessment services to advance safer, more effective cell and gene therapies. We provide a comprehensive suite of trusted assays—such as ONE-seq®, GUIDE-seq™, DEUX-seq™, Amplicon-seq™, Guide Profiler™, Guide Select™, and SAFER Detection™—that enable developers to detect, nominate, and confirm gene editing outcomes with high sensitivity and regulatory alignment. In January 2025, SeQure DX™ was acquired by MaxCyte, Inc., a leading cell engineering company, to form the core of MaxCyte’s Cell & Gene Therapy (CGT) Services business. Together, we provide an integrated solution that combines world-class cell engineering and comprehensive gene editing risk assessment services, helping therapeutic developers mitigate risk in their programs, accelerate timelines, and enable regulatory confidence from discovery through clinical stage and beyond.

SeQure DX Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage

SeQure DX Org Chart

Sample employees and titles
Name Title Contact
Keith Joung Lead Translator at Arena Bioworks
Email
Joe Mohr Senior Director of Business Development
Email
Thomas Mullen Building Winning Teams, Products
View
Douglas Smith
Email

Employees by Management Level

Director 1 profile
Senior / Lead 1 profile
Individual contributor 1 profile

Compare Similar Companies to SeQure DX